ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitors

S. V. Liu; R. Dziadziuszko; S. Viteri; F. Cappuzzo; S. Comis; V. Gabarre; C. Chevalier; T. Vandewalle; F. Montestruc; B. Vasseur; J. Remon; B. Besse

doi:10.1016/j.lungcan.2025.108516

ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitors

S. V. Liu, R. Dziadziuszko, S. Viteri, F. Cappuzzo, S. Comis, V. Gabarre, C. Chevalier, T. Vandewalle, F. Montestruc, B. Vasseur, J. Remon, B. Besse

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

langue originale	Anglais
Numéro d'article	108516
journal	Lung Cancer
Volume	203
Les DOIs	https://doi.org/10.1016/j.lungcan.2025.108516
état	Publié - 1 mai 2025

Accès au document

10.1016/j.lungcan.2025.108516

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Liu, S. V., Dziadziuszko, R., Viteri, S., Cappuzzo, F., Comis, S., Gabarre, V., Chevalier, C., Vandewalle, T., Montestruc, F., Vasseur, B., Remon, J., & Besse, B. (2025). ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitors. Lung Cancer, 203, Article 108516. https://doi.org/10.1016/j.lungcan.2025.108516

@article{2b87a4f504174546a25ca83da60a9f8b,

title = "ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitors",

author = "Liu, {S. V.} and R. Dziadziuszko and S. Viteri and F. Cappuzzo and S. Comis and V. Gabarre and C. Chevalier and T. Vandewalle and F. Montestruc and B. Vasseur and J. Remon and B. Besse",

year = "2025",

month = may,

day = "1",

doi = "10.1016/j.lungcan.2025.108516",

language = "English",

volume = "203",

journal = "Lung Cancer",

issn = "0169-5002",

}

Liu, SV, Dziadziuszko, R, Viteri, S, Cappuzzo, F, Comis, S, Gabarre, V, Chevalier, C, Vandewalle, T, Montestruc, F, Vasseur, B, Remon, J & Besse, B 2025, 'ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitors', Lung Cancer, VOL. 203, 108516. https://doi.org/10.1016/j.lungcan.2025.108516

ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitors. / Liu, S. V.; Dziadziuszko, R.; Viteri, S. et al.
Dans: Lung Cancer, Vol 203, 108516, 01.05.2025.

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

TY - JOUR

T1 - ARTEMIA phase 3 study

T2 - A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitors

AU - Liu, S. V.

AU - Dziadziuszko, R.

AU - Viteri, S.

AU - Cappuzzo, F.

AU - Comis, S.

AU - Gabarre, V.

AU - Chevalier, C.

AU - Vandewalle, T.

AU - Montestruc, F.

AU - Vasseur, B.

AU - Remon, J.

AU - Besse, B.

PY - 2025/5/1

Y1 - 2025/5/1

UR - http://www.scopus.com/inward/record.url?scp=105001369730&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2025.108516

DO - 10.1016/j.lungcan.2025.108516

M3 - Article

AN - SCOPUS:105001369730

SN - 0169-5002

VL - 203

JO - Lung Cancer

JF - Lung Cancer

M1 - 108516

ER -

Liu SV, Dziadziuszko R, Viteri S, Cappuzzo F, Comis S, Gabarre V et al. ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitors. Lung Cancer. 2025 mai 1;203:108516. doi: 10.1016/j.lungcan.2025.108516